Literature DB >> 7166180

Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites.

G Maurer, E Schreier, S Delaborde, H R Loosli, R Nufer, A P Shukla.   

Abstract

A total of 16 metabolites of bromocriptine could be isolated from rat bile and incubates of rat liver cell preparations using [6-methyl-14C]bromocriptine as substrate. Separation and purification was achieved by reversed-phase liquid chromatography and preparative thin-layer chromatography in conjunction with radioactivity monitoring. Structure elucidation was based on spectroscopic data (UV, IR, NMR, EI- and FD-MS) and the results of amino acid analysis after acid hydrolysis. Based on the identified metabolites four principal transformation process could be described: -Hydrolytic cleavage of the amide bridge leading to the formation of 2-bromolysergic acid amide (3) and 2-bromolysergic acid (7). -epimerization at position 8 of the bromolysergic acid moiety to the iso-derivatives (isobromocriptine, 2-bromo-isolysergic acid (6), its amide (1), etc.) -regiospecific oxidation at position 8' in the proline fragment generating stereoisomeric 8'-hydroxy-bromocriptines (21-24) -further oxidation of the 8'-hydroxylated derivatives by either the introduction of a second hydroxy group at position 9' to give dihydroxylated derivatives (detected as conjugates with glucuronic acid: metabolites 29, 30 and 31), or the opening of the proline ring under formation of the metabolites 4 and 5 containing glutamic acid instead of proline (7', 8'-seco- 8'-carboxy-bromocriptines). It is suggested that the primary and principal metabolic attack occurs at the proline fragment of the drug. In contrast to the biotransformation of ergoline compounds, none of the bromocriptine metabolites detected showed oxidative transformations in the lysergic acid half of the molecule.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7166180     DOI: 10.1007/BF03189631

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  4 in total

Review 1.  Preparation of isolated rat liver cells.

Authors:  P O Seglen
Journal:  Methods Cell Biol       Date:  1976       Impact factor: 1.441

2.  Human plasma levels of some anti-migraine drugs.

Authors:  J Meier; E Schreier
Journal:  Headache       Date:  1976-07       Impact factor: 5.887

3.  Distribution and excretion in the rat and monkey of [82Br] bromocriptine.

Authors:  S P Markey; R W Colburn; I J Kopin; R L Aamodt
Journal:  J Pharmacol Exp Ther       Date:  1979-10       Impact factor: 4.030

4.  Trapping of metabolically generated electrophilic species with cyanide ion: metabolism of 1-benzylpyrrolidine.

Authors:  B Ho; N Castagnoli
Journal:  J Med Chem       Date:  1980-02       Impact factor: 7.446

  4 in total
  9 in total

1.  A new semisynthetic ergot peptide alkaloid: DCN 203-922.

Authors:  R K Giger; H R Loosli; M D Walkinshaw; B J Clark; J M Vigouret
Journal:  Experientia       Date:  1987-10-15

2.  High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4.

Authors:  Irina F Sevrioukova
Journal:  Biochemistry       Date:  2017-06-07       Impact factor: 3.162

3.  Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

4.  Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man.

Authors:  G Maurer; W Frick
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits.

Authors:  F L Tse; J M Jaffe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

6.  Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.

Authors:  G Maurer; E Schreier; S Delaborde; R Nufer; A P Shukla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

7.  Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum.

Authors:  S Granveau-Renouf; D Valente; A Durocher; J M Grognet; E Ezan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.569

Review 8.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

Review 9.  Ergot alkaloids produced by endophytic fungi of the genus Epichloë.

Authors:  Philippe Guerre
Journal:  Toxins (Basel)       Date:  2015-03-06       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.